Diplomat Pharmacy (NYSE: DPLO)started the first quarter with decent revenue growth. This is due in part to its new pharmacy benefit manager (PBM) business, now rebranded as CastiaRx, although the acquisition and integration are cutting into the bottom line -- for now.
Diplomat Pharmacy Integrates With New Leadership
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться